Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Il Dong Holdings Co., Ltd. is a multifaceted corporation primarily engaged in the pharmaceutical and healthcare industry in South Korea. Its core business involves the management and investment in subsidiaries that develop and manufacture pharmaceutical products, including prescription drugs, over-the-counter medications, and health supplements. The company's influence extends to biotechnology, where it invests in research and development to bolster innovations in the medical field. Il Dong Holdings also plays a significant role in the consumer health sector, offering a range of nutraceuticals and wellness products that cater to both local and international markets. As a holding company, it continuously seeks opportunities for growth and diversification within the healthcare domain to maintain a robust presence in the competitive global market. Through strategic management and expansion of its business portfolio, Il Dong Holdings contributes significantly to advancements in health-related solutions, impacting hospitals, pharmacies, and consumers alike. With its headquarters in South Korea, the company integrates its resources and expertise to meet the dynamic demands of the pharmaceutical and healthcare industries effectively.
₩6,020.00
₩290.00 (-4.60%)
Live · 05:29 PM
Operating margin is thin at 2.56%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 10.1% YoY. The question is whether this is cyclical or a structural shift.
Net debt of ₩121.70B represents 13.6x FCF, leverage limits flexibility.
4.0x earnings, 8.9x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩602.06B
▼ -10.1% YoY
Net Income (TTM)
₩31.95B
▼ -61.2% YoY
Op. Margin
3.51%
▲ +2.9pp YoY
ROIC
1.71%
▲ +2.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩7.85B
▲ +422.2% YoY
Op. Cash Flow (TTM)
₩29.77B
▼ -74.5% YoY
Net Debt
₩121.70B
Cash & Equiv.
₩77.81B
3Y CAGR: -4.4%
Continue Research
At a P/E of 4.0 and a price-to-free-cash-flow of 8.9, Il Dong Holdings Co. (000230.XKRX) trades below a two-stage DCF intrinsic value of about KRW 23,741.17 per share, so at KRW 6,020.00 the stock looks undervalued (294.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Il Dong Holdings Co. scores 58/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.1%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 23,741.17 per share for 000230.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 17,805.88. At today's KRW 6,020.00, that puts the stock about 294.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Il Dong Holdings Co. scores 58 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 3.5% operating margin and a 1.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Il Dong Holdings Co. pays a regular dividend of about KRW 5.20 per share per year (typically in quarterly installments), a yield of roughly 0.1% at the current price. That is a payout ratio of about 0.2% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 000230.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. 000230.XKRX currently trades below its estimated intrinsic value and scores 58/100 on quality (mixed). It also yields about 0.1%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.